Advanced search
Publication Cover
OncoTargets and Therapy Volume 14, 2021 - Issue
Submit an article Journal homepage
48
Views
4
CrossRef citations to date
0
Altmetric
Original Research

PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment

Cheng-Yu Chang1 Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, TaiwanORCID Iconhttps://orcid.org/0000-0002-7196-3504
ORCID Icon,
Yi-Chun Lai2 Division of Chest Medicine, Department of Internal Medicine, National Yang Ming Chiao Tung University Hospital, Yi-Lan, Taiwan;3 Faculty of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
,
Yu-Feng Wei4 School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung, Taiwan;5 Department of Internal Medicine, E-Da Cancer Hospital, Kaohsiung, TaiwanORCID Iconhttps://orcid.org/0000-0002-6380-3527
ORCID Icon,
Chung-Yu Chen6 Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, Taiwan;7 College of Medicine, National Taiwan University, Taipei, Taiwan
&
Shih-Chieh Chang2 Division of Chest Medicine, Department of Internal Medicine, National Yang Ming Chiao Tung University Hospital, Yi-Lan, Taiwan;8 Department of Critical Care Medicine, National Yang Ming Chiao Tung University Hospital, Yi-Lan, TaiwanCorrespondence[email protected]
Pages 2301-2309 | Published online: 31 Mar 2021

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Cheng-Yu Chang, Chung-Yu Chen, Shih-Chieh Chang, Yi-Chun Lai & Yu-Feng Wei. (2021) Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non-Small-Cell Lung Cancer. Cancer Management and Research 13, pages 7187-7201.
Read now

Articles from other publishers (3)

Si‐Yu Lei, Hai‐Yan Xu, Hong‐Shuai Li, Ya‐Ning Yang, Fei Xu, Jun‐Ling Li, Zhi‐Jie Wang, Pu‐Yuan Xing, Xue‐Zhi Hao & Yan Wang. (2023) Influence of PD‐L1 expression on the efficacy of EGFR ‐TKIs in EGFR ‐mutant non‐small cell lung cancer . Thoracic Cancer 14:24, pages 2327-2337.
Crossref
Chang-Yao Chu, Chien-Yu Lin, Chien-Chung Lin, Chien-Feng Li, Shang-Yin Wu, Jeng-Shiuan Tsai, Szu-Chun Yang, Chian-Wei Chen, Chia-Yin Lin, Chao-Chun Chang, Yi-Ting Yen, Yau-Lin Tseng, Po-Lan Su & Wu-Chou Su. (2023) Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Scientific Reports 13:1.
Crossref
Andreas Koulouris, Christos Tsagkaris, Anna Chiara Corriero, Giulio Metro & Giannis Mountzios. (2022) Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. Cancers 14:14, pages 3337.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.